RA drug access program offers continued treatment for prior study participants
NCT ID NCT03559686
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program provides ongoing access to certolizumab pegol (Cimzia) for adults with rheumatoid arthritis who took part in earlier open-label studies. Participants receive the standard maintenance dose of 200 mg every two weeks. The goal is to allow continued disease management or a smooth transition to standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
certolizumab pegol (Cimzia)
What this could lead to
If successful, this program could help maintain disease control in people with rheumatoid arthritis who have already benefited from the drug.
What could go wrong
This is not a new trial but a continuation program for a limited group. It does not test new benefits or safety, and results may not apply to the wider RA population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.